OPTIMIZING PRIMARY STROKE PREVENTION (STOP II)

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。这项研究是镰状细胞性贫血中风预防试验（STOP）的后续研究。STOP表明，在患有镰状细胞性贫血（SCA）的儿童中，中风高危儿童可以通过经颅多普勒（TCD）超声筛查来识别，定期输血可将高危患者的年中风发病率从10%降至1%以下。这是第一个在这种疾病的随机试验中预防原发性中风的治疗策略。它提供了一个机会，以减少中风的SCA的人力和财力成本。然而，STOP并没有解决的一些重要问题仍然没有答案，包括治疗必须持续多久。这项试验的重要性在于，它将产生可靠的信息，可供临床医生和家长在做出关于继续输血预防卒中的风险和益处的艰难决定时使用。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The proposed study is a follow-up to the Stroke Prevention Trial in Sickle Cell Anemia (STOP). STOP showed that children at high risk for stroke, among those with sickle cell anemia (SCA), can be identified through screening with transcranial doppler (TCD) ultrasound and that periodic transfusion reduces annual stroke incidence in high-risk patients from 10% to less than 1%. This is the first treatment strategy that prevented primary strokes in a randomized trial in this disease. It provides an opportunity to reduce the human and financial cost of stroke in SCA. However, a number of important questions that STOP was not designed to address remain unanswered, including how long treatment must be continued. The importance of this trial is that it will produce reliable information that can be used by clinicians and parents in making difficult decisions regarding the risks and benefits of continued transfusion for stroke prevention.